home / stock / iphyf / iphyf articles
No one has written and article on Innate Pharma, stock symbol IPHYF. Be the first to contribute and write an article.
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanof...
Two abstracts on SAR443579 (IPH6101), ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate’s second generation ANKET ® for the treatment of relap...
First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024 Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers Five ASCO Annual Meeting 2024 abstracts: ...